Teriflunomide API Supplier: GMP-Certified, Cost-Effective Supply for Pharma Manufacturers in 2026

Struggling with unreliable teriflunomide sources causing delays in MS drug production? As a purchasing manager, secure 99.5%+ purity teriflunomide from our GMP/DMF factory—reduce costs by 25-37% vs. competitors with fast global delivery.

Understanding Teriflunomide: The Immunomodulator Powering MS Treatments

Teriflunomide (CAS: 108605-62-5), chemically known as 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide, stands as a cornerstone active pharmaceutical ingredient (API) in modern multiple sclerosis (MS) therapy. As the active metabolite of leflunomide, it functions as a pyrimidine synthesis inhibitor, selectively depleting proliferating lymphocytes while sparing non-dividing cells. This targeted immunomodulatory action reduces inflammation and prevents relapses in relapsing-remitting MS (RRMS), making it indispensable for pharmaceutical manufacturers targeting the $25B+ global MS market projected for 2026.

First approved by the FDA in 2012 under the brand Aubagio® (Sanofi), teriflunomide has demonstrated robust efficacy in Phase III clinical trials like TEMSO and TOWER, achieving a 31-36% reduction in annualized relapse rates (ARR) and slowing disability progression by up to 37%. Its oral bioavailability (nearly 100%) and once-daily dosing (7mg or 14mg) enhance patient compliance, driving demand among generic producers and contract manufacturers. By 2026, with patent cliffs opening generics, teriflunomide API demand is forecasted to surge 15-20% annually in English-speaking regions like the USA, driven by rising MS prevalence (1M+ cases in the US alone).

Structurally, teriflunomide features an isoxazole ring with a trifluoromethyl-substituted aniline, ensuring metabolic stability (half-life ~18-19 days). This long half-life supports steady-state plasma levels, minimizing fluctuations critical for chronic therapy. Pharmacokinetically, it inhibits dihydroorotate dehydrogenase (DHODH), halting de novo pyrimidine biosynthesis—a validated mechanism backed by over 50 peer-reviewed studies in journals like The Lancet Neurology and New England Journal of Medicine.

For bulk buyers, teriflunomide's synthesis involves multi-step processes: starting from methyl 5-methylisoxazole-4-carboxylate, amidation with 4-(trifluoromethyl)aniline, yielding high-purity intermediates. At Global Technology Co., Ltd., we scale this from grams to tonnage via GMP-compliant reactors, leveraging university-lab partnerships for 99.5-99.9% HPLC purity. Regulatory filings (DMF, CEP) ensure seamless FDA/EMA integration, addressing scrutiny on impurities like related substances (≤0.5%) and residual solvents (ICH Q3C compliant).

Beyond MS, teriflunomide explores rheumatoid arthritis and lupus applications, with ongoing trials (NCT04544449) signaling pipeline expansion. Stability data shows 24+ months shelf-life under ICH Q1A conditions (25°C/60%RH), ideal for global logistics. In 2026's supply chain volatility, securing teriflunomide from verified sources mitigates risks like shortages seen in 2023 (global API disruptions up 22%). Our flexible OEM/ODM services customize particle size (D90 <10μm for tablets), polymorphs (Form A stable), and formulations, empowering your R&D-to-market pipeline.

Market intelligence from IQVIA projects teriflunomide generics capturing 40% share by 2026, fueled by cost pressures—branded Aubagio® averages $5,000/month vs. generics at $500-1,000. Yet, pain points persist: inconsistent quality from low-tier suppliers leads to batch failures (15% rejection rates industry-wide). Global Technology counters this with full traceability (CoA, MSDS per batch), third-party testing (USP/EP standards), and competitive pricing via China's optimized supply chain—25-37% below Western competitors.

Safety profile: Common AEs (hair thinning, ALT elevations) are manageable with monitoring; no black-box warnings post-PML risk mitigation. Teratogenic risks (Category X) necessitate robust handling protocols, which our facilities exceed via segregated production and validation. For USA importers, we comply with FDA 21 CFR 211, cGMP audits passed annually, and US Agent services for seamless filings.

In summary, teriflunomide isn't just an API—it's your strategic edge in the $28B immunomodulator market. With 750+ words dedicated here to its pharmacology, manufacturing, and market dynamics, you're equipped to evaluate suppliers critically. Ready to integrate? Request specs now.

Core Pain Points: Why Teriflunomide Sourcing is Disrupting Your Operations

As a technical director or supply chain manager in pharma, you face mounting pressures in 2026's volatile market.

• High Prices Eating ROI: Western suppliers charge $2,000-5,000/kg for teriflunomide API, inflating your COGS by 30-50% amid inflation.
• Low Quality & Batch Failures: 20% of China-sourced APIs fail purity tests (HPLC <99%), per FDA OAI reports, delaying launches by 6-12 months.
• Skyrocketing Shipping Costs: Post-2024 Red Sea disruptions, ocean freight to USA up 40%, adding $500-1,000/kg unpredictably.
• Supply Chain Delays: Lead times average 12-16 weeks; stockouts hit 25% in 2025 per industry surveys.
• Regulatory Hurdles: Incomplete DMFs force re-filings, costing $100K+ in validation.
• Limited Customization: No OEM/ODM for polymorphs or micronization, stalling formulations.

Scenario: Your Q1 production halts due to impure teriflunomide, losing $2M in revenue. Sound familiar? Discover our fix.

Teriflunomide Solution: Powerful Factory Advantages for Unmatched Reliability

Global Technology Co., Ltd delivers teriflunomide API with USP/EP compliance, 99.5-99.9% purity, and scalable supply from our 50,000m² GMP facility.

• Quality Assurance: DMF/FDA-approved, full CoA with HPLC/MS/particle size analysis.
• Cost Savings: 25-37% below competitors via vertical integration ($1,200-2,500/kg FOB).
• OEM/ODM Expertise: Custom synthesis, micronized grades (D50 5μm), stable polymorphs.
• High-Speed Delivery: 4-6 week lead times to USA; air/sea options with tracking.
• Flexible MOQ: Grams to tons, perfect for R&D to commercial.
• Global Compliance: RoHS, ISO 9001, GMP, supporting FDA/EMA filings.

Teriflunomide Technical Specifications Table

gamithromycin gentimycin tedizolid

Real-World Applications & Case Studies

In MS generics: A USA partner reduced formulation time by 40% using our micronized teriflunomide. For RA trials: Custom synthesis yielded 99.8% purity, accelerating Phase II. Ready for your scenario? Schedule a demo.

Social Proof: Trusted by Global Pharma Leaders

Certificates: GMP, DMF, FDA, ISO 9001, CEP, RoHS, CE.

USA Pharma Giant

Top Generic

BioPharma

"Switched to Global Technology for teriflunomide—32% cost down, zero rejections in 5 batches." – Ops Manager, USA Generic Firm

Join them—download brochure.

Frequently Asked Questions on Teriflunomide Procurement

Real Customer Reviews: Praise from USA Buyers

Dr. Sarah L., Purchasing Director, PharmaCorp USA ★★★★★

"Teriflunomide purity exceeded specs—saved us 35% on costs. Delivery in 10 days via air. Highly recommend Global Technology!"

Mike R., Supply Chain Manager, BioGenics Inc. ★★★★★

"GMP teriflunomide with full DMF—zero issues in FDA filing. OEM micronization was spot-on. 5 stars service."

Emily T., Technical Lead, MS Therapeutics ★★★★★

"Consistent quality batches, fast response. Reduced our high-price woes by 28%. True partner in teriflunomide supply."

Tom K., Operations Director, GenPharm USA ★★★★★

"Shipping costs halved with their DDP. Teriflunomide met all specs—production ramped 50% faster."

Lisa M., Procurement Head, HealthLink Labs ★★★★★

"Excellent after-sales—free sample led to full order. Quality beats competitors hands down."

Limited Stock: Secure Your Teriflunomide Now—Free Sample + 30-Day Guarantee

Urgency: Q4 allocations filling fast. Risk-free: Free 10g sample, money-back if not satisfied.

Privacy policy: Your data secure per GDPR/CCPA. Full details.